Engineered immune cells take aim at Hard-to-Treat cancers
Disease control
Ongoing
This early study tests a new treatment for people with advanced colorectal, pancreatic, or lung cancer that has a specific change in the KRAS gene (called G12V). The treatment uses the patient's own immune cells, which are modified in a lab to better recognize and attack cancer c…
Phase: PHASE1 • Sponsor: Corregene Biotechnology Co., Ltd • Aim: Disease control
Last updated May 26, 2026 10:57 UTC